4D Molecular Therapeutics, Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
4D Molecular Therapeutics, Inc. (FDMT) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $471.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2022-11-08
- 4D Molecular Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2021-12-31 was $433.00K.
- 4D Molecular Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2021 was $433.00K.
- 4D Molecular Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2020 was $0.00.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|
| 2022-09-30 | $471.00K 10-Q · filed 2022-11-08 | ||
| 2021-12-31 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $433.00K 10-K · filed 2022-03-28 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |